Clinical Practice Guideline: Aducanumab Prescribing in Patients with Alzheimer’s

What You Need to Know
•Aducanumab is an amyloid beta-directed human immunoglobulin G1 (IgG1) monoclonal antibody indicated for the treatment of Alzheimer’s disease (AD).
•It works by binding to both aggregated soluble and insoluble forms of Aβ, which includes oligomers and fibrils.
•Treatment with Aducanumab should be initiated in patients with Mild Cognitive Impairment (MCI) due to AD or mild ADdementia stage of disease, the population in which treatment was initiated in clinical trials. There are no safety or effectiveness data on initiating treatment at earlier or later stages of the disease.
•It should be noted continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials (see references 1-3 for drug trial information).
•The full process of evaluation, selection and treatment should be managed by the Memory Disorders Clinic in Neurology; the general practitioner/PCP should make a referral to Neurology (614-293-4969) as soon as cognitive decline/memory disorder is suspected.